Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts
Epistemonikos ID: 6f8954dfe6b45bd0630ce3becf88562ee0517da9
First added on: May 10, 2024